Comment on FR Doc # 2026-10128
Amneal Pharmaceuticals, LLCSupportBusiness
Summary: Amneal Pharmaceuticals supports the DEA's proposed rule to improve transparency and address drug shortages but recommends several specific improvements. They advocate for reinstating annual quota submissions, establishing definitive processing timelines, creating an expedited resubmission pathway, and prioritizing quota allocation for API manufacturers.
Comments are attached to this submission.